비침습적 산전 검사(NIPT) 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 구성 요소별, 모드별, 단계별

Non-invasive Prenatal Testing Market is anticipated to expand from $7.4 billion in 2024 to $28.8 billion by 2034, growing at a CAGR of approximately 14.8%. The Non-invasive Prenatal Testing (NIPT) Market encompasses advanced screening methods for chromosomal abnormalities in fetuses using maternal blood samples. This market is driven by the demand for safer, more accurate prenatal diagnostics, reducing the need for invasive procedures. Technological advancements in genetic sequencing and increased awareness are propelling market growth, with a focus on early detection, reliability, and accessibility in prenatal care.

The Non-invasive Prenatal Testing (NIPT) Market is experiencing robust growth, primarily propelled by advancements in genomic technologies and increased awareness among expectant parents. The cell-free DNA testing segment is the top-performing sub-segment, driven by its high accuracy and ability to detect chromosomal abnormalities early in pregnancy. Within this segment, the trisomy detection tests, particularly for Down syndrome, are leading in performance. The microdeletion testing sub-segment follows closely, reflecting the growing demand for comprehensive genetic screening. The services segment, encompassing genetic counseling and diagnostic services, is the second-highest performing segment, as it supports informed decision-making for parents. Next-generation sequencing technology is gaining momentum, offering enhanced precision and reduced turnaround times. Innovative partnerships between healthcare providers and diagnostic companies are fostering market expansion. The integration of artificial intelligence in data analysis is further optimizing test accuracy and efficiency, indicating promising opportunities for sustained growth in the NIPT market.

Market Snapshot:

The Non-invasive Prenatal Testing (NIPT) market is witnessing a dynamic shift in market share, driven by competitive pricing strategies and innovative product launches. Established companies are enhancing their portfolios with advanced testing solutions, while new entrants focus on affordability and accessibility. The market is characterized by a diverse range of offerings that cater to varying consumer needs, emphasizing the importance of technological advancements and cost-effective solutions. This competitive landscape is further enriched by collaborations and partnerships, which are pivotal in expanding market reach and enhancing product efficacy. Competition in the NIPT market is fierce, with key players vying for dominance through strategic alliances and continuous innovation. Regulatory frameworks, particularly in North America and Europe, play a crucial role in shaping market dynamics, ensuring compliance and quality standards. These regulations, while stringent, foster a competitive environment that encourages technological innovation and market expansion. The market's trajectory is influenced by factors such as increasing demand for early and accurate prenatal diagnosis and the growing awareness of genetic disorders. This comprehensive analysis underscores the importance of strategic planning and regulatory compliance in achieving sustained market growth.

Geographical Overview:

The Non-invasive Prenatal Testing (NIPT) market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads due to advanced healthcare infrastructure and high awareness of prenatal testing. The region's strong focus on early disease detection and prevention further drives market expansion. Europe follows, with increasing adoption of NIPT driven by supportive government policies and rising demand for safer prenatal screening methods. In Asia Pacific, the market is growing rapidly, propelled by a large population base and improving healthcare facilities. Countries like China and India are emerging as significant growth pockets, with increasing healthcare expenditure and awareness. Latin America and the Middle East & Africa are also showing potential for growth. In these regions, rising disposable income and improving healthcare access contribute to the increasing adoption of NIPT. These emerging markets are recognizing the benefits of early and non-invasive prenatal diagnostics, paving the way for future expansion.

Key Trends and Drivers:

The Non-invasive Prenatal Testing (NIPT) market is experiencing robust growth, driven by increasing awareness and acceptance of prenatal diagnostics. A significant trend is the growing preference for non-invasive methods over traditional invasive techniques due to their safety and accuracy. Technological advancements in genomics and bioinformatics are enhancing test precision, making NIPT more reliable and accessible. Furthermore, the declining costs of sequencing technologies are making NIPT more affordable, thus broadening its adoption across various demographics. Another key driver is the rising maternal age, which increases the risk of chromosomal abnormalities, thereby boosting demand for early and accurate testing. Additionally, supportive government policies and insurance coverage expansions are facilitating market growth. The market is also witnessing increased competition, leading to innovation and improved service offerings. Opportunities abound in emerging markets where healthcare infrastructure is improving. Companies focusing on expanding their test portfolios and geographical presence are poised to capitalize on these promising trends.

Restraints and Challenges:

The Non-invasive Prenatal Testing (NIPT) market is confronted with several significant restraints and challenges. A primary challenge is the high cost of testing, which limits accessibility in low-income regions and among uninsured populations. This financial barrier restricts the market's potential reach and adoption. Additionally, there is a lack of awareness and education among expectant parents and healthcare providers about the benefits and limitations of NIPT. This gap in understanding can lead to underutilization and mistrust of the technology. Regulatory and ethical concerns also pose a challenge, as differing international guidelines and cultural perspectives can impede market expansion. Moreover, the market faces technical challenges, such as the need for highly accurate and reliable results, which require continuous technological advancements and investments. Finally, competition from traditional prenatal testing methods, which are often more established and trusted, can hinder the growth of the NIPT market. These factors collectively present hurdles to the widespread adoption of NIPT.

Key Players:

Natera, Illumina, Myriad Genetics, Ariosa Diagnostics, Berry Genomics, BGI Genomics, Quest Diagnostics, Progenity, PerkinElmer, Roche Diagnostics, Invitae, Genomic Health, Yourgene Health, Fulgent Genetics, BioReference Laboratories

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Screening Tests
  • 4.1.2 Diagnostic Tests
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Consumables
  • 4.2.2 Instruments
  • 4.2.3 Software
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Laboratory Developed Tests (LDTs)
  • 4.3.2 Clinical Services
  • 4.3.3 Consultation Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Next-Generation Sequencing
  • 4.4.2 Microarray
  • 4.4.3 PCR
  • 4.4.4 Rolling Circle Amplification
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Trisomy Detection
  • 4.5.2 Microdeletion Syndrome Detection
  • 4.5.3 Sex Chromosome Aneuploidy Detection
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Diagnostic Laboratories
  • 4.6.3 Specialty Clinics
  • 4.6.4 Research Institutes
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Reagents
  • 4.7.2 Kits
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 In-house
  • 4.8.2 Outsourced
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Early-Stage Screening
  • 4.9.2 Late-Stage Screening

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Mode
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Mode
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Mode
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Mode
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Mode
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Mode
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Mode
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Mode
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Mode
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Mode
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Mode
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Mode
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Mode
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Mode
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Mode
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Mode
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Mode
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Mode
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Mode
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Mode
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Mode
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Mode
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Mode
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Mode
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Natera
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Illumina
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Myriad Genetics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Ariosa Diagnostics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Berry Genomics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 BGI Genomics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Quest Diagnostics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Progenity
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 PerkinElmer
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Roche Diagnostics
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Invitae
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Genomic Health
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Yourgene Health
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Fulgent Genetics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 BioReference Laboratories
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us